Group items tagged

The head of a US pharmaceutical company has defended his company's decision to raise the price of a 62-year-old medication used by Aids patients by over 5,000%. Turing Pharmaceuticals acquired the rights to Daraprim in August. CEO Martin Shkreli has said that the company will use the money it makes from sales to research new treatments. The question here is whether it is morally defendable to increase revenue by increasing prices to an amount poor people cannot afford. He says the extra money will go to research, but is it worth making the medicine too expensive for poor people?